title: Neem leaf glycoprotein restores the impaired chemotactic activity of peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients by maintaining CXCR3/CXCL10 balance.
abstract: Interaction between CXCL10 and CXCR3 is dysregulated in head and neck squamous cell carcinoma (HNSCC) and hampers chemotaxis of cytotoxic cells at tumor site. In continuation of the demonstration of significant immunomodulatory effects of neem leaf preparation (NLP), the active ingredient of NLP is characterized as a glycoprotein (NLGP). NLGP is responsible for in vivo immunomodulation to restrict the growth of mice tumors. Effect of NLGP in rectification of the dysregulated IFN gamma dependent chemokine and its receptor CXCR3 splice variants was investigated. Upregulated expression of CXCR3B in HNSCC-PBMC were downregulated following in vitro NLGP treatment. Unchanged expression of CXCR3A+B by NLGP with downregulation of the CXCR3B indirectly suggests the upregulation of the CXCR3A, responsible for cellular migration. However, stimulation of healthy-PBMC with NLGP maintains physiological homeostasis of CXCL10 and increases IFN gamma secretion. The suppressed chemotaxis of HNSCC-PBMC could be restored either by in vitro treatment with NLGP or during use of NLGP stimulated PBMC supernatant as a chemoattractant. Neutralization studies confirmed that the chemoattraction process is guided by both receptor (CXCR3A) and its ligand (CXCL10). Neutralization of the IFN gamma in PBMC culture in presence of NLGP unexpectedly increases the intracellular release of CXCL10, suggesting the NLGP mediated IFN gamma independent release of CXCL10. Interestingly, downregulation of the CXCL10 release was detected after IFN gamma neutralization in absence of NLGP and IFN gamma receptor neutralization in presence of NLGP. Efficacy of NLGP in restoration of the dysregulation of the chemokine signaling may be utilized to design new immunotherapeutic protocol.
authors.affiliation: Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, India. krish_nicholas@yahoo.co.in <krish_nicholas@yahoo.co.in>
authors.forename: Krishnendu
authors.initials: K
authors.lastname: Chakraborty
authors.forename: Anamika
authors.initials: A
authors.lastname: Bose
authors.forename: Smarajit
authors.initials: S
authors.lastname: Pal
authors.forename: Koustav
authors.initials: K
authors.lastname: Sarkar
authors.forename: Shyamal
authors.initials: S
authors.lastname: Goswami
authors.forename: Diptendu
authors.initials: D
authors.lastname: Ghosh
authors.forename: Subrata
authors.initials: S
authors.lastname: Laskar
authors.forename: Utpala
authors.initials: U
authors.lastname: Chattopadhyay
authors.forename: Rathindranath
authors.initials: R
authors.lastname: Baral
mesh_terms: D000328:Adult; D000818:Animals; D031601:Azadirachta / Q000737:chemistry*; D002294:Carcinoma, Squamous Cell / Q000276:immunology*; D054357:Chemokine CXCL10 / Q000502:physiology*; D002634:Chemotaxis, Leukocyte; D005260:Female; D006023:Glycoproteins / Q000494:pharmacology*; D006258:Head and Neck Neoplasms / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D008297:Male; D051379:Mice; D008875:Middle Aged; D018515:Plant Leaves / Q000737:chemistry; D054367:Receptors, CXCR3 / Q000502:physiology*; D015398:Signal Transduction
chemical_list: C114753:CXCL10 protein, human; C515187:CXCR3 protein, human; D054357:Chemokine CXCL10; D006023:Glycoproteins; D054367:Receptors, CXCR3; D007371:Interferon-gamma